✦ LIBER ✦

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase

✍ Scribed by Hagop M. Kantarjian; Jianqin Shan; Terry Smith; Moshe Talpaz; Peter Kozuch; Mary Beth Rios; Jorge Cortes; Francis J. Giles; Susan O'Brien

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 106 KB
Volume: 92
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20011115)92:10<2501::aid-cncr1600>3.0.co;2-n

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Terminal deoxynucleotidyl transferase in

Terminal deoxynucleotidyl transferase in the blastic phase of chronic myelogenous leukemia: An indicator of response to vincristine and prednisone therapy

✍ Masao Tanaka; Tsuguhiro Kaneda; Yutaka Hirota; Shonen Yoshida; Koichi Kitajima 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB 👁 1 views

Chronic myelogenous leukemia in nonlymph

Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was

Complete hematologic and cytogenetic res

Complete hematologic and cytogenetic response to 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase : A case report and review of the literature

✍ Alvaro Aguayo; Jorge E. Cortes; Hagop M. Kantarjian; Miloslav Beran; Varsha Gand 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## BACKGROUND. T-cell lymphoid blastic phase (BP) transformation is rare in chronic myelogenous leukemia (CML). 2-amino-9-␤-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. ## METHODS. The authors present a case of a 48-year